Verano Holdings (VRNO) Cost of Revenue (2021 - 2026)
Verano Holdings' (VRNO) quarterly Cost of Revenue came in at $109.2 million in Q1 2026, down 0.93% year-on-year from $110.2 million in Q1 2025, and up 8.21% on a QoQ basis from $100.9 million in Q4 2025.
Verano Holdings (VRNO) Cost of Revenue (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Cost of Revenue data on file, last reported at $109.2 million in Q1 2026.
- On a quarterly basis, Cost of Revenue fell 0.93% year-over-year to $109.2 million in Q1 2026; TTM through Mar 2026 was $407.0 million, a 6.77% decrease from a year earlier, with the FY2025 full-year figure at $408.0 million, down 6.13% from the prior year.
- Cost of Revenue for Q1 2026 stood at $109.2 million, up from $100.9 million in the prior quarter.
- Over the last five years, Cost of Revenue for VRNO reached as high as $125.5 million in Q2 2022 and fell as low as $1.1 million in Q1 2022.
- Historically, Cost of Revenue has averaged $104.1 million across 5 years, with a median of $108.3 million in 2024.
- Across the five-year window, Cost of Revenue surged 11104.85% in 2023 and slipped 17.36% in 2025, its largest moves.
- Year by year, Cost of Revenue stood at $122.6 million in 2022, then retreated by 2.46% to $119.6 million in 2023, then decreased by 7.45% to $110.7 million in 2024, then decreased by 8.81% to $100.9 million in 2025, then grew by 8.21% to $109.2 million in 2026.
- Per Business Quant data, the three most recent Cost of Revenue figures were $109.2 million in Q1 2026, $100.9 million in Q4 2025, and $107.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 2.01 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 641.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 2.59 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 133.40 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 2.36 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 13.80 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 586.00 Mn |
| 10 | Verano Holdings | 1.99 Bn | 1.91 Bn | 98.98 Mn | 109.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 109.20 Mn |
| Mar 31, 2026 | 109.20 Mn |
| Dec 31, 2025 | 100.92 Mn |
| Dec 31, 2025 | 100.92 Mn |
| Sep 30, 2025 | 107.57 Mn |
| Sep 30, 2025 | 107.57 Mn |
| Jun 30, 2025 | 89.29 Mn |
| Jun 30, 2025 | 89.29 Mn |
| Mar 31, 2025 | 110.23 Mn |
| Mar 31, 2025 | 110.23 Mn |
| Dec 31, 2024 | 110.67 Mn |
| Dec 31, 2024 | 110.67 Mn |
| Sep 30, 2024 | 107.59 Mn |
| Sep 30, 2024 | 107.59 Mn |
| Jun 30, 2024 | 108.05 Mn |
| Jun 30, 2024 | 108.05 Mn |
| Mar 31, 2024 | 108.35 Mn |
| Mar 31, 2024 | 108.35 Mn |
| Dec 31, 2023 | 119.58 Mn |
| Dec 31, 2023 | 119.58 Mn |